Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for
the treatment of participants with generalized myasthenia gravis (gMG).